Geron to Present at Needham Virtual Healthcare Conference
08 avr. 2020 16h30 HE
|
Geron Corporation
MENLO PARK, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a...
Geron Provides COVID-19 Related Business Update
02 avr. 2020 08h00 HE
|
Geron Corporation
MENLO PARK, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical development biopharmaceutical company, today announced an update to information from...
Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
26 mars 2020 08h00 HE
|
Aprea Therapeutics
BOSTON, March 26, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Onconova Therapeutics Announces Completion of Enrollment of Phase 3 INSPIRE Trial, Provides a Corporate Update, and Reports 2019 Financial Results
24 mars 2020 16h05 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics to Provide Corporate Update and Full Year 2019 Financial Results
18 mars 2020 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., March 18, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Geron Corporation Reports Fourth Quarter and Full Year 2019 Financial Results and 2020 Milestones
12 mars 2020 16h05 HE
|
Geron Corporation
MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat,...
Onconova Therapeutics Announces Participation in Two Upcoming International Conferences
18 févr. 2020 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova Therapeutics to Present Update at the 2020 BIO CEO & Investor Conference in New York City
04 févr. 2020 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
30 janv. 2020 07h30 HE
|
Aprea Therapeutics
BOSTON, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Onconova Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market
03 janv. 2020 13h27 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel...